ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate

• ChemBase编号: 177
• 分子式: C14H16N2O2
• 平均质量: 244.28904
• 单一同位素质量: 244.12117776
• SMILES: O(C(=O)c1n(C(c2ccccc2)C)cnc1)CC
• Canonical SMILES: CCOC(=O)c1cncn1C(c1ccccc1)C
• InChI: InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3
• InChIKey: NPUKDXXFDDZOKR-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
• IUPAC传统名: etomidate
• 商标名: Amidate; Hypnomidate
• 别名: ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; Etomidic acid; Etomidate; Amidate; 1-(1-phenylethyl)-imidazole-5-carboxylic acid ethyl ester

登记号

• CAS号: 33125-97-2
• MDL号: MFCD00869295; MFCD00867535
• PubChem SID: 160963640
• PubChem CID: 36339
• ATC码: N01AX07
• CHEMBL: 23731
• Chemspider ID: 33418
• DrugBank ID: DB00292
• KEGG ID: D00548
• 美国药典/FDA物质标识码: Z22628B598
• 维基百科标题: Etomidate

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 0
• LogD (pH = 5.5): 2.4663537
• LogD (pH = 7.4): 2.4993365
• Log P: 2.4997861
• 摩尔折射率: 69.5923 cm^3
• 极化性: 26.606922 Å^3
• 极化表面积: 44.12 Å^2
• 可自由旋转的化学键: 5
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 2.66
• LOG S: -2.71
• 溶解度: 4.77e-01 g/l

分子性质

理化性质

• 溶解度: 63.2 mg/L
• 熔点: 68 - 70°C
• 沸点: 392°C (737.6°F)
• 疏水性(logP): 2.667; 2.9

安全信息

• 保存条件: -20°C

药理学性质

• 作用靶点: GABA transporter
• 给药途径: Intravenous
• 排泄: Renal (85%) and biliary (15%)
• 半衰期: 75 minutes
• 代谢: Ester hydrolysis
• 蛋白结合率: 75%
• 法定药品分级: POM (UK)
• 妊娠期药物分类: D (United States)

产品相关信息

• 纯度: 95%; 95+%; 98%
• 成盐信息: Free Base

详细说明

DrugBank - DB00292

• Drug Groups: approved
• Description: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]
• Indication: Used in the induction of general anesthesia.
• Pharmacology: Etomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.
• Toxicity: Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.
• Half Life: 75 minutes.
• Protein Binding: 76%, primarily to serum albumin.
• Elimination: Approximately 75% of the administered dose is excreted in the urine during the first day after injection.
• External Links: Wikipedia; Drugs.com

Selleck Chemicals - S1329

Research Area: Neurological Disease
Biological Activity:
Etomidate is a GABAA receptors agonist at GABAA receptors . Etomidate is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia and for sedation for short procedures such as reduction of dislocated joints and cardioversion. [1]

参考文献

• http://en.wikipedia.org/wiki/Etomidate